Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor.
Recent studies have demonstrated a role for microvascular and tubulointerstitial injury in some models of salt-sensitive hypertension. We utilized a model of post-cyclosporin A (CsA) nephropathy and hypertension to test the hypothesis that treatment with an angiogenic factor aimed at ameliorating the microvascular and renal injury would prevent the development of hypertension. CsA was administered with a low-salt diet for 45 days, resulting in a renal lesion characterized by afferent arteriolopathy, focal peritubular capillary loss, and tubulointerstitial fibrosis. Rats were then placed on a high-salt diet and randomized to receive either vascular endothelial growth factor (VEGF(121)) or vehicle for 14 days. Placement of rats with established CsA nephropathy on a high-salt diet results in the rapid development of salt-sensitive hypertension. VEGF(121) treatment resulted in lower blood pressure, and this persisted on discontinuing the VEGF. VEGF(121) treatment was also associated with a decrease in osteopontin expression, macrophage infiltration, and collagen III deposition and markedly stimulated resolution of the arteriolopathy (20.9 +/- 7.8 vs. 36.9 +/- 6.1%, VEGF vs. vehicle, P < 0.05). In conclusion, CsA-associated renal microvascular and tubulointerstitial injury results in the development of salt-sensitive hypertension. Treatment of animals with established CsA nephropathy with VEGF reduces the hypertensive response and accelerates histological recovery. The vascular protective effect of VEGF may be due to the improvement of arteriolopathy. Angiogenic growth factors may represent a novel strategy for treating CsA-associated hypertension and renal disease.
Kang
D H
DH
Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington 98195, USA. dkang@bcm.tmc.edu
Kim
Y G
YG
Andoh
T F
TF
Gordon
K L
KL
Suga
S
S
Mazzali
M
M
Jefferson
J A
JA
Hughes
J
J
Bennett
W
W
Schreiner
G F
GF
Johnson
R J
RJ
D000818:Animals; D002196:Capillaries / Q000473:pathology; D003094:Collagen / Q000378:metabolism; D016572:Cyclosporine / Q000633:toxicity*; D016228:Endothelial Growth Factors / Q000494:pharmacology*; D006977:Hypertension, Renal / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D007166:Immunosuppressive Agents / Q000633:toxicity*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D008222:Lymphokines / Q000494:pharmacology*; D008264:Macrophages / Q000502:physiology; D008297:Male; D053495:Osteopontin; D051381:Rats; D017207:Rats, Sprague-Dawley; D012079:Renal Circulation / Q000187:drug effects; D012795:Sialoglycoproteins / Q000096:biosynthesis; D017673:Sodium Chloride, Dietary / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D007166:Immunosuppressive Agents; D008222:Lymphokines; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; D017673:Sodium Chloride, Dietary; C506897:Spp1 protein, rat; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D053495:Osteopontin; D016572:Cyclosporine; D003094:Collagen